ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: FR-PO889

Characteristics and Treatment Patterns of a Real-World Lupus Nephritis Cohort Based on Primary Physician Specialty

Session Information

Category: Glomerular Diseases

  • 1203 Glomerular Diseases: Clinical, Outcomes, and Trials

Authors

  • Gairy, Kerry, GSK, Brentford, Middlesex, United Kingdom
  • Hoskin, Ben, Adelphi Group, Macclesfield, Cheshire, United Kingdom
  • Bell, David, Adelphi Group, Macclesfield, Cheshire, United Kingdom
  • Massey, Olivia, Adelphi Group, Macclesfield, Cheshire, United Kingdom
  • Amelio, Justyna, GSK, Stevenage, Hertfordshire, United Kingdom
  • Liakos, Alexander, GSK, Brentford, Middlesex, United Kingdom
  • Abramino levy, Roger, GSK, Collegeville, Pennsylvania, United States
Background

Real-world data describing clinical characteristics and treatments of patients with lupus nephritis (LN) are limited. We describe characteristics and treatment patterns of patients with LN managed by rheumatologists and nephrologists.

Methods

This secondary analysis (GSK study 208683) used survey data of physicians and their patients with LN, enrolled in the 2015 Adelphi Real World Disease Specific Programme (GSK study 205086). Patients (≥18 years) with an LN diagnosis and their treating rheumatologists/nephrologists completed survey forms. Data relating to characteristics, treatment patterns, and disease burden were extracted and compared using Mann-Whitney, Pearson's chi-squared and Fisher's exact tests.

Results

Overall, 38 rheumatologists and 113 nephrologists provided data for 819 patients with LN; 26.9% were provided by a rheumatologist and 73.1% by a nephrologist. Most patients were primarily managed by the responding physician (85.2%), although input was obtained from a range of healthcare practitioners (HCPs). Care for nephrologist-managed patients was shared by more HCPs from other specialties compared with rheumatologist-managed patients. Nephrologists saw significantly more patients with moderate to severe LN than rheumatologists (p<0.01) although LN histological class distribution was similar. Significant differences (p<0.001) were observed between rheumatologist- and nephrologist-managed patients respectively, for current kidney dysfunction (48.2% vs 69.9%), mean (standard deviation [SD]) time since diagnosis (364.6 [347.0] vs 296.8 [345.9] weeks), mean (SD) number of prior treatment lines (2.6 [1.1] vs 2.3 [1.1]), and associated systemic lupus erythematosus systemic features (93.2% vs 46.1%). Patient-reported activity impairment and fatigue were similar regardless of treating physician.

Conclusion

In a real-world setting, patients with LN managed primarily by nephrologists had more severe disease and involvement from more specialties than those managed by rheumatologists. Patient-reported experience was similar, reflecting a high overall disease burden regardless of treating physician specialty.

Editorial assistance (GSK-funded): Gosia Carless, PhD, Fishawack Indicia Ltd, UK.

Funding: Commercial support – GSK.

Funding

  • Commercial Support